To broaden the data on S100A4 expression in cardiac disease models we analyzed steady-state concentrations of S100A4 mRNA in animal models mimicking HCM (Mybpc3-targeted KI mice) or dilated cardiomyopathy (DCM, LMNAΔK32 mice) as well as an in vitro hypertrophy 3D model of EHTs (treated with afterload enhancement, AE, or phenylephrine, PE) according to Hirt et al. (2012). Here, S100A4 is linked to heart disorder.